Kestra Medical Q3 FY26 revenue $24.6M (+63% YoY); FY26 guidance raised to $93M

KESTRA MEDICAL TECHNOLOGIES, LTD.

2026-Q3 EPS reported -$1.76 revenue$66,488,000

Revenue of $24.6M, up 63% YoY; gross margin expanded to 52.6% from 43.4%.
Prescriptions written for ASSURE system up 58% to 5,462; driven by market share gains.
GAAP net loss widened to $34.2M vs $21.8M; adjusted EBITDA loss $21.2M vs $16.3M.
FY26 revenue guidance increased to $93M, representing 55% growth over FY25.
Cash and equivalents $291M after December 2025 equity offering of 6.9M shares.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.